End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…
During the Healthcare Expo organized that take place in Taïwan between the 30th of November and the 3rd of December, our partner Tokyo Future Style Taiwan had a booth and presented BIOMIMESYS® technology. Dr Dar-Bin Shieh stayed a lot of time with our partner to discuss with Joseph and his Read more…
One week later after our business trip in Asia, we are lucky to welcome Pr Dar Bin Shieh from National Cheng Kung University (Taiwan) in Lille on the 16th of November. In the morning, we have been invited in OncoLille, we have presented all our work in oncology field with Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
In order to make known BIOMIMESYS technology, Grégory and Nathalie were in Asia in October during one month. The first step was in Japan. We have worked with our partners from AS ONE and JVC Kenwood. We had the opportunity to visit them in AS ONE office in order to Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in vitro modeling. After a nice opening ceremony with a flamenco show, the scientific program begun Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…
BIOMIMESYS® permet de cultiver des cellules en 3D dans des conditions identiques à celle d’un organe humain et en utilisant exclusivement des composés physiologiques. Nous sommes non seulement capables de proposer un environnement dont la composition est celle du tissu désiré, mais qui en plus a les mêmes propriétés mécaniques de rigidité et de porosité.
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of Read more…
Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…
We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
We will have the pleasure to participate in the 13th Annual Meeting on Skin Ageing & Challenges which will be organized on November 17-18, 2022 at Altis Grand Hotel, Lisbon, Portugal and Online. This congress focus to provide answers and to give a future vision and trends on how can Read more…
Nous avons eu le plaisir d’être invités par notre distributeur Dutscher, et en particulier par Romain Guegan, à présenter lors de la journée Necker-Imagine organisée à l’INEM (Institut Necker Enfants Malades) le 3 novembre dernier. Elodie a eu l’occasion de présenter aux chercheurs présents notre technologie BIOMIMESYS® pour une culture Read more…
Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
We are pleased to welcome Rita as a commercial on board of HCS Pharma company. Graduate in commerce international and in a commercial bachelor training, Rita decide to get on board of the promise HCS PHARMA company as work-study student. Her purpose ? Bring a commercial support in the dermocosmetology Read more…
Our project leader Méryl and our CBO Mathieu are currently attending CellME (Cell Manufacturing & Engineering) Forum taking place these days in Berlin, Germany. Méryl had the chance to present his work and the advantages of BIOMIMESYS® for organoid culture earlier today: Please feel free to discuss with them on Read more…
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…
It will be a pleasure to meet you in the next BIOJAPAN (Oct 12 – 14 2022) that will take place in Yakoama. We will be present on our partner’s booth, AS ONE corp. (H29). Thanks to our partners in Asia, AS ONE corp. and JVC Kenwood corp. and our Read more…